Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.

Pfizer Inc. and Moderna Inc. have been developing ... people who have received two shots of existing vaccines. Japan is currently providing booster shots for certain segments of the population ...

Robert F. Kennedy Jr. petitioned the FDA to revoke authorization of the shots when they were in high demand and thousands of ...

to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron subvariants BA.4 and BA.5. The US regulator has cleared a 30 µg booster dose of a new ...

What happened to the need to end commuting and presenteeism? Or to our gratitude for healthcare workers or our resolution to ...

The two companies have submitted data from a phase 1 trial in support of the booster dose to the ... of either the Pfizer/BioNTech or Moderna COVID-19 vaccines for people with "moderately to ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

Additionally, vaccines with similar technology show that antibodies can migrate: For instance, with Moderna’s Covid-19 vaccine, antibodies are shown to move to sites of infection in the nose.

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...